Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
Details : AP-188 (N,N-dimethyltryptamine) is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke...
Brand Name : AP-188
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2023
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Dalmore Group
Deal Size : $10.0 million
Deal Type : Public Offering
Details : The capital raised will be used for research, development, and program management costs related to the completion of the Phase 1 DMT (N, N-dimethyltryptamine) study currently underway as well as Phase 2a stroke and traumatic brain injury (TBI) studies.
Brand Name : DMT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 03, 2023
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Dalmore Group
Deal Size : $10.0 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?
Reset All
